The following is a description of a study from one of the many researchers that our organization has funded.

Modulation of Fibrosis by Statins in Murine Model of Scleroderma

Gabriella Lakos, M.D., Ph.D.
University of Illinois at Chicago
Chicago, Illinois
Scleroderma is a chronic, progressive multi-system connective tissue disorder of unknown etiology with no effective treatment. Five-year mortality approaches 40%, largely due to scarring of vital organs. Dr. Lakos’s study provides insight in the pathogenesis of scleroderma, and facilitates evaluating potential new treatments. Results from Dr. Lakos’s studies may indicate if statins (a widely used cholesterol lowering drug with potent anti-inflammatory and vasoprotective properties) can be considered reasonable and safe therapeutic interventions in scleroderma.
You may return to the list of research that we have funded.